Programmed Death-1 Restrains the Germinal Center in Type 1 Diabetes

Area of Science:

• Immunology
• Autoimmunity
• Cancer Immunotherapy

Background:

• Programmed death-1 (PD-1) pathway is crucial for immune regulation, inhibiting T and B cell activity.
• PD-1 blockade has transformed cancer treatment but can induce autoimmune side effects, including autoantibody production.
• The precise role of PD-1 in germinal center (GC) reactions and its link to autoimmunity remain controversial.

Purpose of the Study:

• To investigate the role of the PD-1 pathway in regulating germinal center reactions in the context of type 1 diabetes.
• To elucidate the mechanisms by which PD-1 inhibition might accelerate autoimmune responses.

Main Methods:

• Utilized tetramer technology to phenotype insulin-specific CD4+ T and B cells in non-obese diabetic (NOD) mice.
• Examined the effects of PD-1 or PD-L1 deficiency and PD-1 blockade on T follicular helper cells, GC B cells, and autoantibody production.
• Assessed the impact of targeting the insulin peptide:MHC class II complex on PD-1 blockade-induced effects.

Main Results:

• PD-1 or PD-L1 deficiency, and PD-1 blockade, led to the expansion and enhanced survival of insulin-specific T follicular helper CD4+ T cells.
• These conditions were associated with increased germinal center B cells and heightened insulin autoantibody production.
• Treatment with an antibody targeting the insulin peptide:MHC class II complex reduced the impact of PD-1 blockade on germinal centers.

Conclusions:

• PD-1 pathway inhibition can dysregulate germinal centers, promoting the expansion of self-reactive T follicular helper cells and autoantibody production.
• This study provides a mechanistic explanation for autoimmune side effects observed with PD-1 pathway inhibitors.
• Targeting the self-peptide:MHC class II complex presents a potential strategy to limit autoimmunity induced by checkpoint blockade therapies.